Regulatory Compliance

Boston – October 01, 2026 -- HoneyNaps, an AI-based sleep health technology company, has completed registration as a clinical research organization (CRO) with South Korea's National Enterprise for Clinical Trials (KoNECT), broadening its role in pharmaceutical and medical device trials worldwide.

HoneyNaps secures CRO registration with KoNECT, expanding multicenter trial capacity

The company has supported clinical trials involving more than 10,000 participants and can now operate multicenter, multidisciplinary studies under its new CRO status. The registration formalizes HoneyNaps' position as a provider of standardized sleep data analysis for pharmaceutical companies, medical device developers, and research organizations.

San Jose, Calif. – October 01, 2026 -- AppZen has launched ZenLM Plus, a family of finance-specialized large language models that outperformed seven frontier AI models on expense audit accuracy while cutting inference costs, the company announced.

Houston and Düsseldorf – October 01, 2026 -- Uniper has reserved future production capacity from Syzygy Plasmonics' NovaSAFTM biogas-to-sustainable aviation fuel platform, joining a growing list of fuel buyers backing the technology ahead of a final investment decision on the company's first commercial plant in Uruguay.

Uniper locks in dual-certified SAF supply to meet EU mandate volumes

The agreement secures capacity under Syzygy's dual-certified pathway, which qualifies for both bio-based and RFNBO (renewable fuels of non-biological origin) SAF categories under European Union mandates. The deal adds commercial weight to Syzygy's planned NovaSAF facilities across Central and South America, with NovaSAF-1 in Uruguay now approaching final investment decision.

Denver – October 01, 2026 -- LandGate has expanded its spatial intelligence platform to track more than 2,100 data center facilities across 10 European markets, adding site-level power, permitting and connectivity data to its existing U.S. coverage.

The expansion follows LandGate's acquisition by Wood Mackenzie in June 2026 and positions the company as a supplier of site-selection intelligence for hyperscale and AI-driven data center developers operating across Europe.

UK leads European coverage with 500+ facilities amid 70 GW of pending connection requests

The United Kingdom dominates LandGate's European dataset with more than 500 tracked facilities concentrated in the London and Slough corridor, where power connection requests now exceed 70 GW. Germany follows with 450+ facilities centered in Frankfurt, where the EnEfG Act will require new builds to hit a PUE of 1.2 or lower from July 2026 and shift to 100% renewable electricity by 2027.

Dallas – October 01, 2026 -- Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has accepted and granted priority review to Nanoscope Therapeutics' New Drug Application for MOGENRY (sonpiretigene isteparvovec, MCO-010), an optogenetic gene therapy for inherited retinal dystrophies (IRDs). If approved by the Ministry of Health, Labour and Welfare, MOGENRY would become the first disease-agnostic treatment available to IRD patients in Japan, a condition caused by mutations across more than 250 genes that leads to progressive photoreceptor loss and blindness.

Beijing and Tel Aviv – October 01, 2026 -- ADAMA Ltd. (SZSE: 000553) has launched Actavan®, a plant-based fungicide for grapes, in Australia and New Zealand, offering growers a zero-residue tool against Botrytis with no pre-harvest interval.

Beet-extract compound activates grapevine immune defenses before infection

Actavan® is a Systemic Acquired Resistance (SAR) elicitor derived from beet extract. It triggers genes that produce enzymes degrading pathogen cell walls while stimulating antimicrobial phytoalexins, activating the plant's own defense response ahead of fungal attack.

Dublin – October 01, 2026 -- Temu has added a dedicated geographical indications (GI) category to its Brand Registry Portal, giving rightsholders a direct channel to flag potential GI infringements across all of the platform's markets.

Temu builds GI tool after 100+ meetings with European trade groups

The feature stems from feedback gathered across more than 100 meetings with trade associations, chambers of commerce and start-up networks in Europe, where sellers cited complexity as a recurring barrier to online trade. GI products derive their value from a specific geographical origin, carrying economic and cultural weight for the producers and regions behind them.

A Temu spokesperson said the company aims to give GI rightsholders a clearer path to work directly with the platform to protect the authenticity tied to their products' heritage.

Taipei – October 01, 2026 -- Cervoz Technology has launched the T449 and T459 Series, a new line of MIL-STD-810H compliant M.2 2280 NVMe SSDs built for defense, aerospace, transportation, and industrial automation systems operating in harsh environments.

Drives deliver PCIe Gen4 speeds of up to 5,085 MB/s read and 4,765 MB/s write

The T449 and T459 Series support PCIe Gen4 x4 NVMe interfaces, pairing industrial 3D TLC NAND with LDPC error correction, wear leveling, and End-to-End Data Protection to sustain performance during continuous workloads such as mission computers, AI edge platforms, video recording, and industrial data logging.

Valby, Denmark – October 01, 2026 -- H. Lundbeck A/S reported that 60% of participants in its Phase IV THRIVE trial achieved 'much improved' or 'very much improved' status on a standardized patient scale after switching to eptinezumab, marketed as VYEPTI, following an inadequate response to a prior CGRP-targeting preventive migraine therapy.

Trial enrolled 164 adults who had failed one prior CGRP preventive treatment

The 24-week, open-label, multicenter trial (NCT06701526) was conducted in the United States and enrolled 164 adults with at least eight monthly migraine days who had previously used either a subcutaneous anti-CGRP monoclonal antibody or a preventive gepant, but had not received eptinezumab. Participants started on 100 mg of eptinezumab, escalating to 300 mg at week 12, with 147 receiving both infusions; 84% (138/164) completed the trial.

Helsinki – October 01, 2026 -- ICEYE and Nokia have agreed to jointly develop secure, sovereign low Earth orbit (LEO) satellite communications systems for governments and defense customers, with the first satellites expected to launch in 2028.

Nations will own and control the full satellite communications stack

The partnership targets a system in which governments hold full ownership of the satellites, ground segment and terminals, removing reliance on foreign commercial operators' terms of service. The broadband LEO network is designed to serve defense, border security, emergency services and disaster response missions with high-throughput, low-latency connectivity over priority mission areas.